Browse by author
Lookup NU author(s): Professor Stephen O'Brien
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2013 Springer Science+Business Media New York. All rights reserved. The original recognition of leukemia in the nineteenth century and the story of our progressive understanding of the biology and the development of treatment of chronic myeloid leukemia (CML) have been well reviewed in recent years [1, 2]. Today the diagnosis of CML usually presents few problems. In contrast, planning a therapeutic strategy for a patient who presents in chronic phase and monitoring a patient who starts treatment with a tyrosine kinase inhibitor (TKI) present a number of challenges. The same is true for a patient in chronic phase whose disease proves resistant to initial treatment with a TKI. Even more difficult may be the issue of how best to treat a patient presenting in or progressing to an advanced phase of CML. In this chapter, we will review some of the essentials of diagnosis of CML, which will be mostly self-evident to practicing hematologists, but the main focus will be on available treatment options, the results to date of using these various options, and guidance on therapeutic strategy.
Author(s): O'Brien SG, Goldman JM
Editor(s): Peter H. Wiernik, John M. Goldman, Janice P. Dutcher, Robert A. Kyle
Publication type: Book Chapter
Publication status: Published
Book Title: Neoplastic Diseases of the Blood
Online publication date: 27/07/2012
Place Published: New York
Library holdings: Search Newcastle University Library for this item